Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women. (APR)
This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2015 by INC Research
Hetero Labs Ltd.
Janssen R&D Ireland
Lupin Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Prinston Pharmaceutical Inc.
Sciegen Pharmaceuticals Inc.
Silarx Pharmaceuticals Inc
Strides Arcolab Ltd.
Sunshine Lake Pharma
Teva Pharmaceuticals USA
Information provided by (Responsible Party):
First received: November 27, 2006
Last updated: December 14, 2015
Last verified: December 2015
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is currently recruiting participants.|
|Estimated Study Completion Date:||January 2099|
|Estimated Primary Completion Date:||January 2099 (Final data collection date for primary outcome measure)|